This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Kanna
South African succulent (Sceletium tortuosum) with mesembrine-alkaloid pharmacology that's pharmacologically a dual SSRI + PDE4 inhibitor — yields anxiolytic + mild mood-lift + pro-cognitive signal…
Aliases (9)
Overview
What is Kanna?
South African succulent (Sceletium tortuosum) with mesembrine-alkaloid pharmacology that's pharmacologically a dual SSRI + PDE4 inhibitor — yields anxiolytic + mild mood-lift + pro-cognitive signal at 25 mg standardized Zembrin extract. Best evidence: Terburg 2013 fMRI (single-dose amygdala dampening), Chiu 2014 RCT (cognitive flexibility + executive function), Reay 2020 RCT (acute anxiolysis under experimental stress). Critical safety: the SRI mechanism makes it functionally a mild antidepressant — DO NOT combine with SSRIs, SNRIs, MAOIs, tramadol, MDMA, 5-HTP, DXM, St John's Wort, or any serotonergic compound (serotonin syndrome risk, potentially fatal with MAOI combinations). For Dylan (no current meds, no MAO inhibitors): WATCH-LIST as a situational anxiolytic for pre-event anxiety or post-stim parasympathetic reset, not a daily nootropic. Zembrin is the cleanest research-grade form; raw plant powder is dose-unreliable.
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
Community's most common pairing (dopamine.club: n=35). Theanine's α-wave / glutamatergic modulation complements kanna's serotonergic anxiolysis without serot…
Common pairing (dopamine.club: n=34). Kanna takes the adrenergic edge off caffeine; caffeine offsets any mild sedative effect of kanna. For Dylan specificall…
Calmative complement; no pharmacological interaction. Common kanna user stack element.
Adaptogen complement; no significant serotonergic component in rhodiola at typical doses. Common community pairing (dopamine.club: n=27).
GABAergic + cortisol-modulating; complementary mechanism, no serotonergic overlap. Community pairing (dopamine.club: n=21).
Cognitive support; minimal serotonergic activity (Bacopa has very mild SERT signal but functionally below threshold). Community pairing (dopamine.club: n=22).
Different anxiolytic mechanism (GABA-A modulation, not serotonergic). No pharmacological interaction expected. Community pairing (dopamine.club: n=20). Cavea…
Dopaminergic precursor; community pairing (n=18). No serotonergic conflict; theoretical complementary action on mood. Safe.
Anxiolytic peptide with minimal serotonergic involvement (some 5-HT and dopamine modulation). No documented interaction with kanna; theoretical complementary…
(serotonergic + opioid)
entactogens and recreational SRIs
What to Expect
- Onset30-60 min oral
- Onsetand offset are smooth (no acute peak/crash)
Side Effects & Safety 11
Side Effects
- 1Mild headache (~5-15%; usually first 1-3 doses, fades within a week)
- 2Dry mouth, increased thirst
- 3Mild nausea (1-10%; more frequent at >50 mg)
- 4Sleep onset shift or mild insomnia if dosed after noon (5-10%)
- 5Paradoxical anxiety (~10-15% of anxiety-prone users in subset reports) — same initiation pattern as low-dose SSRIs
- 6Mild jitteriness/restlessness
- 7Mild fatigue (community-reported at higher doses)
- 8Mild GI upset (nausea, occasional loose stools)
- 9Mild appetite suppression
- 10Mild brain-fog or "flatness" at chronic daily dosing (SSRI-class effect emerging)
- 11Mydriasis (pupil dilation at higher doses — serotonergic indicator)
When to Stop
- Serotonin syndrome — central risk. See Drug Interactions section for full breakdown. Almost all reported cases involve co-administration with another serotonergic drug (SSRI, MAOI, tramadol, MDMA). Solo kanna serotonin syndrome at therapeutic doses (25-50 mg Zembrin) is not documented as of 2026 in published case literature.
- Hypomania switch — rare; documented for SSRIs generally, theoretical for kanna in bipolar-spectrum users. Anyone with bipolar diagnosis or family history should treat kanna as functionally an SSRI for this risk.
- Mood-lowering / depression — paradoxical worsening reported in a subset of community users at chronic high doses (analogous to SSRI initiation worsening in some patients). Community reports n=5 ("depression" side-effect) in dopamine.club aggregate.
- Acute psychosis — not documented for kanna specifically; theoretical concern in psychotic-spectrum users (apply SSRI-class caution).
- Withdrawal/discontinuation effects — at chronic daily dosing, abrupt cessation may produce mild rebound anxiety (analogous to mild SSRI discontinuation syndrome). Tapering not formally studied but advisable after >4 weeks of daily use.
- Days 1-7: serotonergic initiation watch — paradoxical anxiety, jitteriness, GI upset peak in first week. If sharp anxiety surge, drop to 8 mg or stop.
- Weeks 2-4: tolerance assessment — does the 25 mg dose still produce subjective effect? If yes, continue cycling protocol. If no, stop daily use; intermittent use only.
- Months 1+: chronic-use side-effect watch — emotional blunting, anhedonia, libido changes (SSRI-class chronic effects). Stop if any emerge.
- Bipolar disorder / family history — SSRI-class hypomania trigger risk. Apply standard antidepressant caution; avoid without psychiatrist input.
- Pregnancy/breastfeeding — no human safety data. Avoid.
- Pediatric / age <18 — no efficacy or safety data. Avoid.
- Severe hepatic impairment — alkaloid metabolism predominantly hepatic; no formal dose-adjustment data.
- History of seizures — theoretical concern; not well-characterized. Consult physician.
- Pre-anesthesia / pre-surgery — discontinue 1-2 weeks before surgery to avoid intraoperative serotonergic interactions with anesthetic agents (tramadol, fentanyl-class with weak serotonergic activity, ondansetron).
References
Terburg et al. 2013 — Acute effects of Sceletium tortuosum (Zembrin) on the human amygdala (Neuropsychopharmacology, PMID 23903032)
central fMRI study; single 25 mg dose reduces amygdala reactivity to fear + amygdala-hypothalamus connectivity.
View StudyChiu et al. 2014 — Cognition effects of Zembrin targeting PDE4 in healthy subjects (Evidence-Based Complementary and Alternative Medicine, PMID 25389443)
21 healthy adults, 3-week crossover, cognitive flexibility + executive function improvements at 25 mg/day.
View StudyReay et al. 2020 — Zembrin ameliorates experimentally-induced anxiety in healthy volunteers (Human Psychopharmacology, PMID 32761980)
acute anxiolysis on Maastricht Acute Stress Test.
View StudyNell et al. 2013 — Randomized, double-blind, placebo-controlled trial of Zembrin in healthy adults (Journal of Alternative and Complementary Medicine, PMID 23441963)
3-month safety/tolerability at 8 mg and 25 mg/day; well-tolerated, no significant hematology/biochemistry changes.
View StudyBrendler et al. 2021 — Sceletium for managing anxiety, depression, and cognitive impairment: regulatory review (PMC8762184, PMID 33588735)
comprehensive Western review of clinical + regulatory + safety profile.
View StudyManganyi et al. 2021 — A chewable cure "kanna": biological and pharmaceutical properties of Sceletium tortuosum (Molecules, PMC8124331)
pharmacological review including anti-inflammatory, antioxidant, antidepressant, anxiolytic effects.
View StudySceletium tortuosum effects on anxiety: systematic review and meta-analysis (Phytomedicine Plus 2023)
4 studies / 117 patients; moderate effect size; not yet definitive.
View StudyHoffman et al. 2020 — Ergogenic effects of 8 days of Sceletium tortuosum supplementation on mood, visual tracking, and reaction in recreationally trained men and women (J Strength Cond Res, PMID 32740286)
60 active 20-35yo subjects; reactive-performance gain at 25 mg Zembrin × 8 days; no mood effect in this population.
View StudyToxicological safety assessment of standardized Sceletium tortuosum extract (Zembrin) in rats (PMID 25301237)
sub-chronic animal toxicology; no mortality or target-organ toxicity.
View StudyPatnala & Kanfer 2009 — Pharmacological actions of Sceletium tortuosum and its principal alkaloids (PMID 21798331)
foundational pharmacology review of mesembrine alkaloids.
View StudySmith et al. 1996 — Sceletium tortuosum in an in vivo model of psychological stress (PMID 20816940)
early animal model anxiolytic data.
View StudyPLT Health Solutions Zembrin product information
manufacturer reference; standardization specs (2:1 extract, 0.35% mesembrine, 0.6% mesembrenol + Δ7-mesembrenone); NDI notification details.
View StudyNIH Office of Dietary Supplements — Kanna safety in dietary supplements (OPSS)
operational supplement-safety overview including serotonergic interaction warnings.
View StudyPsychonautWiki: Kanna
dose tiers, route of administration profiles, harm-reduction information; community-aggregated subjective effect reports.
View StudyFrontiers in Plant Science 2024 — Sceletium bibliometric review (Skeletons in the closet?)
bibliometric view of research landscape; identifies clusters in pharmacology, phytochemistry, ethnobotany.
View StudyMesembryanthemum tortuosum / Sceletium tortuosum — Wikipedia
botany, taxonomy, history, legal status, ethnobotany.
View StudyErowid — Sceletium tortuosum experience reports
first-person subjective effect reports.
View StudySouth African Khoi-San benefit-sharing agreement (2010 Biodiversity Act + Zembrin licensing)
ethical sourcing context.
View StudyLatest research
- meta-analysisSceletium tortuosum effects on anxiety — systematic review and meta-analysis4 studies / 117 patients; promising anxiolytic signal but inconclusive — could not guarantee efficacy at meta-level.
- reviewA chewable cure "kanna" — biological and pharmaceutical properties of Sceletium tortuosum (Manganyi et al.)Survey of antimicrobial, anti-inflammatory, antioxidant, antidepressant, anxiolytic, cognitive effects; emphasizes mesembrine standardization variance across products.
- reviewSceletium for managing anxiety, depression and cognitive impairment — modern regulatory review (Brendler et al.)Comprehensive 2021 review of clinical + regulatory + safety profile; no documented herb-drug interactions to date but theoretical serotonergic risks emphasized.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.